Herpes News and Research

RSS

Herpes is an infection caused by two different but closely related viruses — herpes simplex virus type 1 (HSV-1) or cold sores and herpes simplex virus type 2 (HSV-2) or genital herpes. Both are easy to catch. They have similar symptoms (blisters or sores) and both can occur on different parts of the body. When the infection is on the mouth, it is called oral herpes. When it is on or near the sex organs, it is called genital herpes. There is no cure for herpes. Treatments are available to speed up the healing of the genital sores.

Merck first quarter sales increase 1% to $11.6 billion for 2011

Merck, known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2011.

30 Apr 2011

Mylan launches Famciclovir Tablets

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Famciclovir Tablets, 125 mg, 250 mg and 500 mg, the generic version of Novartis' Famvir® Tablets, a treatment for herpes.

20 Apr 2011

LMP1 viral protein needs TRAF6 cellular protein to promote B cell activation signaling pathways: Study

By identifying a surprising association of two intracellular proteins, University of Iowa researchers have laid the groundwork for the development of new therapies to treat B cell lymphomas and autoimmune disease.

20 Apr 2011

People with infectious mononucleosis, low UVB exposure may face high risk of MS

New research suggests that people who are exposed to low levels of sunlight coupled with a history of having a common virus known as mononucleosis may be at greater odds of developing multiple sclerosis than those without the virus.

19 Apr 2011

African genital herpes strains are more infectious than the U.S. virus

Strains of genital herpes in Africa are far more virulent than those in the United States, researchers at Harvard Medical School report, a striking insight into a common disease with important implications for preventing HIV transmission in a region staggered by the HIV/AIDS epidemic.

15 Apr 2011

Tansy plant can help treat herpes: Study

A folk remedy may be an effective treatment for the sexually transmitted disease herpes according to Dr Solomon Habtemariam from the University of Greenwich's School of Science and Professor Francisco Parra at the Universidad de Oviedo in Spain.

15 Apr 2011

Non-specific recurring genital symptoms could be undiagnosed herpes

A study of patients attending sexual health clinics in Gothenburg found that just four out of ten patients with genital herpes actually knew that they had the disorder. However, a third of those who did not realise that they had been infected reported typical symptoms at a follow-up visit, reveals a thesis from the University of Gothenburg, Sweden.

12 Apr 2011

FluCide nanoviricide drug reduces overall leukocytes in lung tissue of influenza model

NanoViricides, Inc. reports that post-infection treatment with its optimized FluCide drug candidates resulted in significant reduction in lung tissue presence of leukocytes, and in particular, that of eosinophils in a lethal influenza infection animal model.

8 Apr 2011

Post-infection treatment with NanoViricides FluCide reduces lung lesions caused by lethal influenza infection

NanoViricides, Inc. reports that post-infection treatment with its optimized FluCide™ drug candidates resulted in dramatic reduction in the number of lung lesions that are caused by a lethal influenza virus infection. These findings were seen in the most recent H1N1 influenza animal study.

5 Apr 2011

Study suggests causal link between HSV1 and Alzheimer's disease

Laboratories at the University of New Mexico (UNM), Brown University, and House Ear Institute (HEI) have developed a new technique to observe herpes simplex virus type 1 (HSV1) infections growing inside cells. HSV1, the cause of the common cold sore, persists in a latent form inside nerve cells.

5 Apr 2011

Abbott and Enanta's ABT-450/r Phase 2 study results against HCV presented at EASL meeting

Abbott and Enanta Pharmaceuticals today announced 12-week results from a Phase 2 study of ABT-450/r, an investigational, oral protease inhibitor being developed for the treatment of hepatitis C infection.

4 Apr 2011

Entry inhibitors can provide first new hepatitis B & D treatments for many years

Promising new viral hepatitis data presented today at the International Liver CongressTM show that entry inhibitors --a new mechanism of action for drugs to treat viral hepatitis -- could provide the first new hepatitis B and hepatitis D treatments for many years.

2 Apr 2011

Cellectis 2010 total operating revenues increase 55% to EUR 15.8M

Cellectis, the genome engineering specialist, has announced its consolidated financial results for the financial year ended December 31, 2010.

31 Mar 2011

Mary Ann Liebert to launch new 'Shingles and PHN' open access journal

Shingles and PHN, a new, bimonthly open access peer-reviewed journal, will be launched in fall 2011 by Mary Ann Liebert, Inc., publishers.

30 Mar 2011

FDA clears new BD ProbeTec Qx Amplified DNA Assays to detect HSV 1 and 2

Clinicians now have a new tool to help diagnose symptomatic patients with Herpes Simplex Viruses -- one of the most common sexually transmitted infections in the world.

From BD (Becton, Dickinson and Company) 29 Mar 2011

Merck & Co receives FDA approval for Zostavax vaccine to treat shingles

The Food and Drug Administration today approved the use of Zostavax, a live attenuated virus vaccine, for the prevention of shingles in individuals 50 to 59 years of age. Zostavax is already approved for use in individuals 60 years of age and older.

25 Mar 2011

Watson introduces Famciclovir tablets to treat cold sores, genital herpes

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. has launched Famciclovir tablets, 125 mg, 250 mg and 500 mg, the generic version of Novartis' Famvir following approval of its Abbreviated New Drug Application by the U.S. Food and Drug Administration.

22 Mar 2011

NanoViricides reports improved efficacy with optimized FluCide nanoviricide drug candidates for influenza

NanoViricides, Inc. reported dramatically improved antiviral efficacy with its optimized FluCide™ drug candidates in its most recent animal study.

21 Mar 2011

Inhibitex fourth quarter net loss increases to $7.0 million

Inhibitex, Inc. today announced its financial results for the fourth quarter and year ended December 31, 2010, and provided an update on recent clinical and corporate developments.

11 Mar 2011

BioAlliance Pharma awarded €2 million in funding to study Lauriad mucoadhesive technology

BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, today announced the award of €2 million in funding over 30 months from the « Fond Unique Interministériel » (a French program supporting collaborative research projects) including an amount of €743,000 specifically allocated to BioAlliance Pharma.

5 Mar 2011